By Michael Kim NASDAQ:CPSS READ THE FULL CPSS RESEARCH REPORT After the market closed on 10/31/24, Consumer Portfolio Services (NASDAQ:CPSS) reported 3Q24 earnings results. For the quarter, CPSS reported net income of $4.8 million, or $0.20 per share – a penny shy of our $0.21 EPS estimate. Relative to our model, despite more favorable revenues, … Read more
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its 510(k) premarket filing submission for the semi-active mBôs TKA System. … Read more
Economy, Finance and Industry Minister Antoine Armand and Prime Minister Michel Barnier at the Elysée Palace, Paris, October 15, 2024. JULIEN MUGUET FOR LE MONDE The legacy of the Olympic and Paralympic Games has a lasting impact beyond just sports facilities and urban developments; it will also be reflected in economic growth figures. The Olympics are … Read more
NASDAQ:GRCE | NASDAQ:ACST Since the recording of this interview, the company has changed its name to Grace Therapeutics and is now trading under NASDAQ:GRCE. John Viglotti: Hello, and welcome to Virtual Investor Conferences. My name’s John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we’re very pleased you joined … Read more
NYSE:PLX John Viglotti: Hello, and welcome to Virtual Investor Conferences. My name is John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we’re very pleased you joined us for our next presentation from Protalix Biotherapeutics. Their session will be moderated by John Vandermosten. He’s the Senior Biotechnology Analyst with … Read more
